Evidence mapPaperPMID 36217155Full record

ArticleAlzheimer's research & therapy2022

Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice.

Zongyang Li, Xiangbao Meng, Guoxu Ma, Wenlan Liu, Weiping Li, Qian Cai, Sicen Wang, Guodong Huang, Yuan Zhang

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Zongyang Li *Department of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Sungang Westroad, Futian District, Shenzhen, 518035, China.
Xiangbao Meng *Department of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Sungang Westroad, Futian District, Shenzhen, 518035, China.
Guoxu MaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 151, Malianwa North Road, Haidian District, Beijing, 100193, China.
Wenlan LiuDepartment of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Sungang Westroad, Futian District, Shenzhen, 518035, China.
Weiping LiDepartment of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Sungang Westroad, Futian District, Shenzhen, 518035, China.
Qian CaiCollege of Pharmacy, Jinan University, No. 855 Xingye Avenue East, Panyu District, Guangzhou, 511486, China.
Sicen WangSchool of Medicine, Xi'an Jiaotong University, No.76, Yanta Westroad, Xi'an, 710061, China.
Guodong HuangDepartment of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Sungang Westroad, Futian District, Shenzhen, 518035, China. huangguodong@email.szu.edu.cn.
Yuan ZhangDepartment of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Sungang Westroad, Futian District, Shenzhen, 518035, China. zhangyuan2019@email.szu.edu.cn.
Shenzhen Second People's Hospital · CNJinan University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PPARγ agonists have been proven to be neuroprotective in vitro and in vivo models of Alzheimer's disease (AD). In the present study, we identified ligustrazine piperazine derivative (LPD) as a novel PPARγ agonist, which was detected by a dual-luciferase reporter assay system. LPD treatment dose-dependently reduced Aβ40 and Aβ42 levels in PC12 cells stably transfected with APP695swe and PSEN1dE9. Intragastric administration of LPD for 3 months dose-dependently reversed cognitive deficits in APP/PS1 mice. LPD treatment substantially decreased hippocampal Aβ plaques in APP/PS1 mice and decreased the levels of Aβ40 and Aβ42 in vivo and in vitro. Moreover, LPD treatment induced mitophagy in vivo and in vitro and increased brain

Indexed as

Alzheimer DiseasePPAR gammaAdenosine TriphosphateAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainCognitionDisease Models, AnimalFluorodeoxyglucose F18GlucoseLuciferasesMiceMice, TransgenicMitophagyPiperazineAdenosine TriphosphateAmyloid beta-PeptidesAmyloid beta-Protein PrecursorFluorodeoxyglucose F18GlucoseLuciferasesPiperazinePPAR gammaPresenilin-1Protein KinasesPyrazinesSequestosome-1 ProteintetramethylpyrazineUbiquitin-Protein LigasesAlzheimer’s diseaseMitochondriaMitophagyPINK1/ParkinPPARγ

Identifiers

PMID36217155
PMCPMC9552451
OpenAlexW4304136631

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.